MedicaidCoverageHigh impact
Silver State Scripts Board Made Changes to the Preferred Drug List Effective August 1, 2025
Nevada Medicaid·NV · Endocrinology, Rheumatology, Dermatology +4 more·Pharmacy
Effective date
Aug 1, 2025
We identified it
Jun 21, 2026
Summary
Silver State Scripts Board updated Nevada Medicaid's Preferred Drug List effective August 1, 2025, with significant changes to insulin coverage (moving most rapid-acting insulins to non-preferred status), new COVID-19 antivirals, and reorganized topical steroid classifications. Multiple drug classes saw preferred status changes that will affect prior authorization requirements and patient access.
Action Required
Immediately: Update prior authorization workflows for Nevada Medicaid patients prescribed rapid-acting insulins (Apidra, Humalog, Novolog products now non-preferred), targeted immunomodulators (Stelara moved to non-preferred, Pyzchiva and Yesintek added as preferred with PA), and other affected drug classes. Verify patient formulary coverage before prescribing. Update EMR alerts for providers to flag when prescribing non-preferred medications that may require step therapy or generate higher patient costs.